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Heart failure remains a significant health problem 
in the Western countries despite the evolution achieved 
in terms of heart disease prevention and medical 
treatment. Its incidence and its prevalence reach 
550,000/year and 5 million respectively in the United 
States. As a consequence, heart failure causes about 
287,000 deaths in the US each year and puts a financial 
burden to the health system of $29.6 billion dollars due 
to the increasing number of hospitalizations especially 
in elderly patients. 1,2  
Cardiac resynchronization therapy (CRT) is a 
relatively recent advance in the management of heart 
failure patients, which has been very hopeful since its 
development. Large trials have established the efficacy 
of CRT in improving functional capacity (MUSTIC, 
MIRACLE) and reducing mortality (COMPANION, 
CARE HF) in patients with advanced heart failure 
(NYHA III-IV), reduced ejection fraction (EF<35%) 
and wide QRS complex >120 - 130 ms (MIRACLE) 3-7. 
Data from meta-analyses also confirm the beneficial 
effect of CRT with respect to mortality from worsening 
heart failure and all cause mortality in patients with 
wide QRS complex. 8-10  
Nevetheless, not all patients suffering from heart 
failure have a prolonged QRS. On the contrary, it has 
been reported that nearly 50% of heart failure patients 
have a QRS < 120 ms. 11 Moreover, CRT has been 
shown to improve haemodynamic variables in patients 
with heart failure and narrow QRS. 12 Achilli et al, 13 
who studied 52 patients, reported that CRT produced 
similar clinical and functional benefit in patients with 
wide or narrow QRS, the cut-off point being 120 ms 
provided they had mechanical dyssynchrony. Bleeker at 
al14 came up with similar results when they compared 
33 patients with normal QRS duration with an equal 
number of subjects with wide QRS. All participants 
ought to have mechanical dyssynchrony >65 ms on 
tissue Doppler imaging (TDI) study. Yu et al15 
confirmed these findings, showing evidence of reverse 
remodelling and clinical improvement in 102 patients 
with heart failure. Half of them demonstrated a normal 
width of the QRS complex and had baseline systolic 
dyssynchrony. Gasparini et al.16 evaluated a total 
number of 376 patients with impaired systolic function 
and concluded that CRT was beneficial in terms of both 
clinical parameters and left ventricular (LV) geometry 
in a long-term basis, regardless of the QRS duration. 
Notably, the patients with a narrow QRS were not 
selected on the basis of mechanical dyssynchrony, but 
they constituted only a small percentage of the whole 
study population (46/376 or 12%). Another meta-
analysis by Jeevanantham et al.17 incorporating data 
from the studies by Yu, Bleeker and Achilli, where the 
patients with narrow QRS were selected on the basis of 
mechanical dyssynchrony, showed that there was a 
significant improvement in mean LVEF and six 
minutes walk distance (6 MWD) at the end of a follow-
up period exceeding 3 months. When results from other 
studies with longer follow up period were included, the 
improvement in the former indices was even more 
impressive.  
The ESTEEM-CRT study on the other hand, 
showed that patients with narrow QRS and mechanical 
dyssynchrony (Ts-SD-12 echocardiographic variable) 
did not benefit from CRT with regard to exercise 
tolerance and reverse remodelling. 18 Moreover, a 
recent study enrolling 90 patients with mechanical 
asynchrony regardless of their QRS width, did not find 
significant difference in the outcome (reduction of 
LVESV by 15% or more) between those with wide or 
narrow QRS after CRT implantation, at the end of the 
follow up period (1±2 months), although there was a 
trend for better outcome in the wide QRS arm (53 vs. 
73% p=0.084). 19  
All these results however, emerge from relatively 
small, non-randomized studies. Subgroup analyses from 
larger, randomized trials may provide more reliable 
information. In the CARE -HF trial, those with QRS 
less than 160 ms did not benefit from CRT.7 The 
MADIT-CRT trial which evaluated the effect of CRT-
D over mere ICD implantation in patients with mild 
heart failure in a randomized manner, showed that 
resynchronization was effective in preventing new heart 
failure events in patients with a baseline QRS of more 
than 150 ms. 20 Similar results were obtained from the 
REVERSE trial. In this study 610 patients with NYHA 
class I/II heart failure, QRS duration >120 ms, LV end-
diastolic dimension >55 mm, and LVEF <40% were 
randomized to active therapy (CRT on) or control (CRT 
off) for 12 months.  A significant reduction in LV end-
diastolic and end-systolic volume indexes and an 
increase in LVEF at 12 months was reported, although 
only for those with a baseline QRS > 140 ms.21  
The first randomized attempt to assess the issue of 
CRT in narrow QRS was the RethinQ study. A total of 
172 patients with a standard indication for an ICD and 
QRS<130 ms, were randomly assigned to receive or not 
a CRT device and were followed up for 6 months. In 
the prespecified group of resynchronised patients with 
normal QRS duration the primary end point of increase 
in O2 consumption by at least 1.0 ml per kg of body 
weight per minute during cardiopulmonary exercise 
was not achieved, in contrast to the rest of the 
participants who received CRT and had a QRS wider 
than 120 ms.22  
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In conclusion, the concept of CRT efficacy in heart 
failure patients with narrow QRS is still under 
evaluation. The initial relatively small non-randomized 
trials have yielded encouraging results. However, data 
from larger randomized studies challenge these 
favourable conclusions and the RethinQ trial, the first 
to address this particular issue in a randomized fashion, 
failed to confirm the usefulness of CRT in this setting. 
Nevertheless, more data from large randomized trials 
are still needed to further elucidate this matter. A new 
study aiming at evaluating the effects of CRT on 
mortality and morbidity of subjects with heart failure 
due to LV systolic dysfunction, already receiving 
optimized medical therapy, with a narrow QRS width 
(< 130 ms) and echocardiographic evidence of 
ventricular dyssynchrony (EchoCRT) is currently 
recruiting patients.23 Interesting results that will 
probably enlighten the field are anticipated due to the 
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